On 30 April 2019, iThera Medical GmbH and Invicro LLC, a Konica Minolta company, announced a unique partnership with the placement of the MSOT inVision platform in Invicro’s in vivo laboratory at its headquarters in Boston, USA. The companies will come together to uniquely offer pharmaceutical, biotechnology and academic sponsors services from the optoacoustic platform that will identify and quantify disease-related biomarkers at both a molecular and anatomical level through pre-clinical full body tomographic scans.
Invicro was founded in 2008 to improve the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, cardiology, and pulmonary. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro’s industry-leading software informatics platforms, VivoQuant and iPACS.
Read the full story in Global Banking & Finance here.